Alsterpaullone induces apoptosis of HepG2 cells via a p38 mitogen‑activated protein kinase signaling pathway

Yin,Peng; Zheng,Nanxin; Dong,Junfeng; Xu,Chunyang; Zhang,Xiaomei; Ding,Guoshan

doi:10.3892/ol.2018.9700

Alsterpaullone induces apoptosis of HepG2 cells via a p38 mitogen‑activated protein kinase signaling pathway

Authors:
- Peng Yin
- Nanxin Zheng
- Junfeng Dong
- Chunyang Xu
- Xiaomei Zhang
- Guoshan Ding
View Affiliations

Affiliations: Department of Organ Transplantation, Changzheng Hospital, Shanghai 200003, P.R. China
Published online on: November 14, 2018 https://doi.org/10.3892/ol.2018.9700
Pages: 1177-1183
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alsterpaullone (Alp) is a small‑molecule inhibitor that targets cyclin‑dependent kinases to inhibit tumor cell activity. However, to the best of our knowledge, the effect of Alp on hepatoblastoma has not been investigated. Therefore, the function of Alp in apoptotic induction of hepatoblastoma cells and a potential mechanism of action were investigated. Results indicated that low doses of Alp (1 µM) significantly induced apoptosis in the HepG2 hepatoblastoma cell line. In vivo experiments of tumor suppression further indicated that Alp (3 mg/kg) exerted an inhibitory effect on HepG2 xenograft tumor growth. Following Alp treatment, the expression level of B‑cell lymphoma 2 (Bcl‑2)‑associated X protein, and cleaved caspase‑3 and ‑9 in HepG2 cells was significantly increased; however, the expression of Bcl‑2 was significantly decreased. In addition, phosphorylation of p38 mitogen‑activated protein kinase (MAPK) significantly decreased Alp‑induced caspase‑3 and ‑9 activation. These results suggested that Alp induces apoptosis and inhibited proliferation via the p38MAPK signaling pathway. Therefore, Alp may be a therapeutic agent for treating hepatoblastoma.

View Figures

View References

1	Ismail H, Broniszczak D, Kaliciński P, Dembowska-Bagińska B, Perek D, Teisseyre J, Kluge P, Kościesza A, Lembas A and Markiewicz M: Changing treatment and outcome of children with hepatoblastoma: Analysis of a single center experience over the last 20 years. J Pediatr Surg. 47:1331–1339. 2012. View Article : Google Scholar : PubMed/NCBI
2	Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH and Meyers RL: Hepatoblastoma state of the art: Pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 26:19–28. 2014. View Article : Google Scholar : PubMed/NCBI
3	Finegold MJ, Lopez-Terrada DH, Bowen J, Washington MK and Qualman SJ: College of American Pathologists: Protocol for the examination of specimens from pediatric patients with hepatoblastoma. Arch Pathol Lab Med. 131:520–529. 2007.PubMed/NCBI
4	Cohen MM Jr: Beckwith-Wiedemann syndrome: Historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol. 8:287–304. 2005. View Article : Google Scholar : PubMed/NCBI
5	Cui C, Wang Y, Wang Y, Zhao M and Peng S: Alsterpaullone, a cyclin-dependent kinase inhibitor, mediated toxicity in HeLa cells through apoptosis-inducing effect. J Anal Methods Chem. 2013:6020912013. View Article : Google Scholar : PubMed/NCBI
6	Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, Meijer L and Kunick C: Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem. 42:2909–2919. 1999. View Article : Google Scholar : PubMed/NCBI
7	Martin CM and O'Leary JJ: Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol. 25:605–615. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lahusen T, De Siervi A, Kunick C and Senderowicz AM: Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Mol Carcinog. 36:183–194. 2003. View Article : Google Scholar : PubMed/NCBI
9	Rivest P, Renaud M and Sanderson JT: Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact. 189:177–185. 2011. View Article : Google Scholar : PubMed/NCBI
10	Soni DV and Jacobberger JW: Inhibition of cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G2 through prophase. Cell Cycle. 3:349–357. 2004. View Article : Google Scholar : PubMed/NCBI
11	Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, Bryant M, Bebenek M, Wang X, Bertrand KC, et al: Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget. 6:21718–21729. 2015. View Article : Google Scholar : PubMed/NCBI
12	Takai N, Kira N, Ishii T, Nishida M, Nasu K and Narahara H: Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pac J Cancer Prev. 12:575–580. 2011.PubMed/NCBI
13	Arion VB, Dobrov A, Göschl S, Jakupec MA, Keppler BK and Rapta P: Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs. Chem Commun (Camb). 48:8559–8561. 2012. View Article : Google Scholar : PubMed/NCBI
14	Overington JP, Al-Lazikani B and Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 5:993–996. 2006. View Article : Google Scholar : PubMed/NCBI
15	Imming P, Sinning C and Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 5:821–834. 2006. View Article : Google Scholar : PubMed/NCBI
16	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The protein data bank. Nucleic Acids Res. 28:235–242. 2000. View Article : Google Scholar : PubMed/NCBI
17	Min J, Huang K, Tang H, Ding X, Qi C, Qin X and Xu Z: Phloretin induces apoptosis of non-small cell lung carcinoma A549 cells via JNK1/2 and p38 MAPK pathways. Oncol Rep. 34:2871–2879. 2015. View Article : Google Scholar : PubMed/NCBI
18	Watanabe K: Current chemotherapeutic approaches for hepatoblastoma. Int J Clin Oncol. 18:955–961. 2013. View Article : Google Scholar : PubMed/NCBI
19	Katzenstein HM, London WB, Douglass EC, Reynolds M, Plaschkes J, Finegold MJ and Bowman LC: Treatment of unresectable and metastatic hepatoblastoma: A pediatric oncology group phase II study. J Clin Oncol. 20:3438–3444. 2002. View Article : Google Scholar : PubMed/NCBI
20	Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P, Dicks-Mireaux C, Phillips A, Vos A and Plaschkes J: Pretreatment prognostic factors for children with hepatoblastoma-results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer. 36:1418–1425. 2000. View Article : Google Scholar : PubMed/NCBI
21	Kumar S and Lavin MF: The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ. 3:255–267. 1996.PubMed/NCBI
22	Nicholson DW and Thornberry NA: Caspases: Killer proteases. Trends Biochem Sci. 22:299–306. 1997. View Article : Google Scholar : PubMed/NCBI
23	Oltvai ZN and Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell. 79:189–192. 1994. View Article : Google Scholar : PubMed/NCBI
24	Strasser A, O'Connor L and Dixit VM: Apoptosis signaling. Annu Rev Biochem. 69:217–245. 2000. View Article : Google Scholar : PubMed/NCBI
25	Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW and Yuan J: Human ICE/CED-3 protease nomenclature. Cell. 87:1711996. View Article : Google Scholar : PubMed/NCBI
26	Thornberry NA and Lazebnik Y: Caspases: Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
27	Park WH and Kim SH: MAPK inhibitors augment gallic acid-induced A549 lung cancer cell death through the enhancement of glutathione depletion. Oncol Rep. 30:513–519. 2013. View Article : Google Scholar : PubMed/NCBI
28	Esmaeili MA, Farimani MM and Kiaei M: Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling pathways, ROS-mediated pathway and mitochondrial dysfunction in hepatoblastoma cancer (HepG2) cells. Mol Cell Biochem. 397:17–31. 2014. View Article : Google Scholar : PubMed/NCBI
29	Cui Y, Lu P, Song G, Liu Q, Zhu D and Liu X: Involvement of PI3K/Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis. Food Chem Toxicol. 92:26–37. 2016. View Article : Google Scholar : PubMed/NCBI